The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG S1404: A phase III randomized trial comparing standard of care adjuvant therapy to pembrolizumab in patients with high risk resected melanoma.
 
Kenneth F. Grossmann
Consulting or Advisory Role - Roche/Genentech
 
Megan Othus
No Relationships to Disclose
 
Ahmad A. Tarhini
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme
Research Funding - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Prometheus
 
Sapna Pradyuman Patel
Stock and Other Ownership Interests - Provectus
Honoraria - Dava Oncology; PCME, Rockpointe; PlatformQ Health
Consulting or Advisory Role - Amgen; Genentech/Roche
Speakers' Bureau - Bristol-Myers Squibb (Mexico); Merck
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Prometheus (Inst); Reata Pharmaceuticals (Inst)
 
James Moon
No Relationships to Disclose
 
Vernon K. Sondak
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck/Schering Plough; Novartis; Provectus
 
John M. Kirkwood
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Genentech; GreenPeptide; Roche
Research Funding - Merck (Inst); Prometheus (Inst)
 
Antoni Ribas
Stock and Other Ownership Interests - Arcus Ventures; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; Kite, a Gilead company
Consulting or Advisory Role - Amgen; Merck